In contrast, transplantation of cells taken from RUNX1/ETO knockdown mice (RE-KD; LNP/siRE-mod primary treatment) resulted in significantly prolonged median survival of 210 days (p < 0.0016) with 50% of the transplanted mice not developing leukaemia at all (Fig. 9c). Here, RUNX1 is linked to leukemia.